S100A9 and type 2 diabetes mellitus: Therapeutic strategies to reduce neutrophilia and NETosis are aimed at disruption of S100A8/S100A9 signalling or their downstream mediators in neutrophils, thus suppressing excessive granulopoiesis as seen in type 2 diabetes.